<DOC>
	<DOC>NCT00412880</DOC>
	<brief_summary>Open label, uncontrolled Phase II trial to assess the efficacy and safety of BI 2536 in second line treatment in sensitive-relapse SCLC patients.</brief_summary>
	<brief_title>BI 2536 Second Line Monotherapy in SCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Small Cell</mesh_term>
	<criteria>Patients with histologically or cytologically confirmed, sensitiverelapse SCLC defined by a relapse 60 days or more after cessation of prior firstline chemotherapy. Patients with at least one measurable lesion, with longest diameter to be recorded as 20 mm or greater. Life expectancy of at least three months and ECOG performance score of 2 or less and written informed consent that must be consistent with ICHGCP Guidelines. More than one prior regimen of chemotherapy, mixed small cell/large cell or combined small cell histology. Symptomatic brain metastases or leptomenigeal disease Patients with ascites, patients who have any other lifethreatening illness or organ system dysfunction, or other malignancies diagnosed within the past five (5) years (other than non melanomatous skin cancer) Absolute neutrophil count (ANC) &lt;1,500/µl, platelet count &lt;100,000/µl, or hemoglobin &lt;9 mg/dl Total bilirubin &gt;1.5 x ULN, aspartame amino transferase (AST) and/or alanine amino transferase (ALT) &gt;2.5 x ULN, or aspartate amino transferase (AST) and/or alanine amino transferase (ALT) &gt;5 x ULN in case of known liver metastases, serum creatinine &gt;2.0 mg/dl (&gt;176 µmol/L, SI Unit equivalent) Chemo, hormone (other than Megace®) or immunotherapy within the past 4 weeks or within less than 4 halflife times of the previous drug prior to treatment with the trial drug Radiation therapy within the past 2 weeks prior to or during treatment with the trial drug Patients with any serious active infection (i.e., requiring an IV antibiotic, antifungal, or antiviral agents), patients with known HIV, hepatitisB or C infection Known or suspected active drug or alcohol abuse Treatment with any other investigational drug within the past 4 weeks or within less than 4 halflife times of the investigational drug Patients with a known preexisting coagulopathy or requiring therapeutic anticoagulation with warfarin (Coumadin ®) Patients with neuropathy (sensory or motor) CTCAE 3</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>